Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $2.84

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have earned a consensus recommendation of “Hold” from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $2.9318.

HCAT has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Health Catalyst in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research report on Wednesday, June 24th. Wells Fargo & Company lifted their price objective on shares of Health Catalyst from $1.00 to $1.75 and gave the company an “equal weight” rating in a research note on Friday, June 26th. Canaccord Genuity Group upped their price objective on shares of Health Catalyst from $2.00 to $3.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Stephens cut their price objective on shares of Health Catalyst from $2.00 to $1.75 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th.

Institutional Investors Weigh In On Health Catalyst

Several hedge funds have recently added to or reduced their stakes in the business. Focus Partners Wealth purchased a new position in shares of Health Catalyst during the 1st quarter valued at about $46,000. nVerses Capital LLC purchased a new stake in shares of Health Catalyst in the fourth quarter worth about $25,000. Cresset Asset Management LLC purchased a new stake in shares of Health Catalyst in the second quarter worth about $39,000. FNY Investment Advisers LLC acquired a new stake in Health Catalyst during the third quarter worth about $45,000. Finally, BNP Paribas Financial Markets grew its holdings in Health Catalyst by 71.7% during the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after acquiring an additional 6,832 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Price Performance

Shares of HCAT opened at $2.04 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.69 and a quick ratio of 1.69. The company’s fifty day moving average price is $1.78 and its 200-day moving average price is $1.72. Health Catalyst has a 1-year low of $0.96 and a 1-year high of $4.11. The firm has a market capitalization of $150.74 million, a PE ratio of -0.55 and a beta of 1.56.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Monday, May 11th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. Health Catalyst had a negative return on equity of 3.52% and a negative net margin of 87.69%.The company had revenue of $70.76 million during the quarter, compared to analyst estimates of $69.24 million. On average, equities research analysts predict that Health Catalyst will post -0.25 EPS for the current year.

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.